| ITK (interleukin‑2–inducible T‑cell kinase) is a Tec‑family non‑receptor tyrosine kinase that is highly enriched in thymocytes and peripheral T cells, where it serves as a central amplifier of T‑cell receptor (TCR) signaling, coupling receptor engagement to phospholipase Cγ1 activation, calcium mobilization, and downstream transcriptional programs that drive T‑cell activation, differentiation, and effector function. The protein contains an N‑terminal pleckstrin homology (PH) domain that binds PI3K‑generated phosphoinositides in the plasma membrane, followed by a Tec homology region with a proline‑rich segment, SH3 and SH2 domains that engage adaptor proteins, and a C‑terminal kinase domain whose activation loop tyrosine is phosphorylated by Lck. TCR engagement with peptide–MHC complexes activates Lck and ZAP‑70, leading to phosphorylation of CD3 ITAMs and the adaptors LAT and SLP‑76; PI3K activity simultaneously generates PtdIns(3,4,5)P3, which recruits ITK via its PH domain to LAT‑rich membrane microdomains, where its SH2/SH3 domains bind phosphorylated SLP‑76 and LAT and position the kinase for transphosphorylation on Y511 by Lck and subsequent autophosphorylation on Y180. Activated ITK phosphorylates PLCγ1 on regulatory tyrosines, which stimulates hydrolysis of PIP2 into IP3 and DAG; IP3 triggers intracellular Ca²⁺ release and sustained Ca²⁺ influx, leading to NFAT activation, while DAG engages Ras–MAPK and PKC pathways, culminating in ERK, NF‑κB, and JNK activation and the coordinated induction of cytokine genes and proliferation‑associated programs. Quantitative analyses of ITK function support its role as a signaling rheostat: graded ITK activity tunes the balance between NFAT and NF‑κB outputs, influences the strength and duration of TCR signaling, and thereby shapes T‑cell fate decisions, including thresholds for positive selection in the thymus and the skewing of CD4⁺ T cells toward Th1, Th2, Th17, or Th9 lineages. ITK deficiency in murine and human systems impairs PLCγ1 phosphorylation, Ca²⁺ signaling, and Th2 cytokine production, leading to defective responses to helminths and altered antiviral immunity, whereas intact or heightened ITK signaling supports robust Th2, Th9, and Th17 responses that contribute to asthma, allergy, and certain autoimmune phenotypes. ITK self‑association through its regulatory domains constrains signaling; engineered disruption of intermolecular self‑association enhances recruitment to LAT complexes and strengthens NFAT activation, indicating that intramolecular and intermolecular contacts in the PH–TH–SH3–SH2 module provide an additional layer of control over kinase output. ITK participates in oncogenic fusions such as ITK–SYK in peripheral T‑cell lymphomas, where constitutive kinase activity drives antigen‑independent signaling, and small‑molecule ITK inhibitors have been developed that modulate TCR‑, CD28‑, and chemokine‑driven responses, with applications being explored in T‑cell lymphomas, graft‑versus‑host disease, and autoimmune inflammation where selective dampening of T‑cell effector pathways is desirable. |
